rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1

Documenti analoghi

• rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses
  di: Bart, P, et al.
  Pubblicazione: (2012)
• Type I interferon-dependent activation of NK cells by rAd28 or rAd35, but not rAd5, leads to loss of vector-insert expression
  di: Johnson, Matthew J., et al.
  Pubblicazione: (2013)
• Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: correspondence
  di: Rujittika Mungmunpuntipantip, et al.
  Pubblicazione: (2022-06-01)
• Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
  di: Hammer, Scott M., et al.
  Pubblicazione: (2013)
• Multiple antibody specificities (gp41, V1V2, and V3) elicited in the phase II multiclade (A, B, C) HIV-1 DNA prime, rAd5 boost vaccine trial
  di: Williams, WB, et al.
  Pubblicazione: (2012)